Please login to the form below

Not currently logged in
Email:
Password:

disease management

This page shows the latest disease management news and features for those working in and with pharma, biotech and healthcare.

The two ‘c’s’ of public health: confounding and causal inference*

The two ‘c’s’ of public health: confounding and causal inference*

So, we have to use observational studies and data to guide and inform our approach to disease management. ... 3. Age cannot be on the causal pathway between coronary heart disease and death.

Latest news

  • Smart watch epilepsy monitor cleared by FDA Smart watch epilepsy monitor cleared by FDA

    The market for wearable devices with healthcare applications is estimated to be around $6bn at the moment, ranging from activity monitors through to diagnostic and disease management aids. ... Last year, trials started of a smart watch intended to

  • The shifting healthcare landscape The shifting healthcare landscape

    Many of these future opportunities rely on companies stepping out of their corner as a developer of medicines and becoming more involved in providing solutions for the entire management of the ... disease - from initial diagnosis right though to ongoing

  • Merck to pilot digital behavioural change programme Merck to pilot digital behavioural change programme

    The German pharmaceutical company will work with Blue Mesa Health to provide the US digital therapeutics firm’s chronic disease prevention programme to diabetes patients. ... Daniel Ruggiero, head of diabetes strategy at Merck, said: “We believe

  • Shire claims EU approval for haemophilia A drug Adynovi Shire claims EU approval for haemophilia A drug Adynovi

    disease management for haemophilia A patients in Europe.”.

  • Lilly signs real-world digital diabetes deal with Livongo Lilly signs real-world digital diabetes deal with Livongo

    Livongo, which wants to redesign chronic disease management, counts four of the seven largest US health plans and over 200 employers among its clients. ... The knowledge we gain from these studies will be incorporated into our diabetes management

More from news
Approximately 4 fully matching, plus 169 partially matching documents found.

Latest Intelligence

  • Implementing eHealth innovation Implementing eHealth innovation

    In this area, I have seen the adoption of eHealth initiatives bring significant benefits in medicine adherence, while the progress in chronic disease management has recently led to industry recognition with ... Medications management and eHealth. The

  • Delivering real patient value Delivering real patient value

    Access to peer-reviewed medical information empowered patients: patients indicated that publications/patient summaries helped them discuss disease management and treatment options with their HCPs and feel in control of their ... disease. Respondents also

  • Medical affairs Medical affairs

    Personalised medicine strategies using targeted approaches are being developed to achieve the best outcomes in the management of a patient’s disease or predisposition to disease. ... The process starts with deep insights into the disease area, product

  • Is it time we stopped talking about adherence? Is it time we stopped talking about adherence?

    Creating partners, fostering engagement, solving problems. The time is long overdue to elevate patients as true partners and active decision-makers in their disease management and treatment course. ... The healthcare professional may be the expert on a

  • Tackling the challenge of non-adherence Tackling the challenge of non-adherence

    Improving patient adherence… is one way of improving this efficiency as there is decreased spending on hospitalisations, re-admissions, disease progression and complications.”. ... health solutions in improving chronic disease management.

More from intelligence
Approximately 0 fully matching, plus 35 partially matching documents found.

Latest appointments

  • Hugh Cole joins Jounce Therapeutics as chief business officer Hugh Cole joins Jounce Therapeutics as chief business officer

    Cole brings over 25 years’experience in biotech including business development, corporate strategy, R&D, alliance management, commercial planning and execution and corporate leadership. ... He has also held roles for Oscient Pharmaceuticals, The

  • Glyconics appoints CEO Glyconics appoints CEO

    UK disease management diagnostics firm Glyconics has appointed Dr Kam Pooni as chief executive officer with immediate effect.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 14 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics